Darolutamide in nmCRPC shows deep PSA responses but some radiographic progression despite low PSA levels.
nmCRPC
Advertisement
Latest News
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
A clinical trial sought to determine if flutamide is more effective with or without PROSTVAC in patients with nmCRPC.
Updated AUA/SUO Guideline on Advanced Prostate Cancer Offers New Recommendations on Imaging, Testing
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.
Dr. Sternberg shares the therapeutic options for nmCRPC patients, how stage at diagnosis impacts these options, and more.
Researchers conducted a study to determine PSA response and MFS in patients with nmCRPC treated with APA.
Existing literature on adverse events in ARSi drugs was examined to determine how the drugs’ side-effect profiles compare.
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Canes discusses the formation of the WellPrept delivery platform and how it aims to boost patient education.
Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.
Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection
Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.
Dr. Cheaib discusses outcomes in patients with non-clear cell RCC with tumor thrombus involvement after surgical treatment.
Advertisement
Trending
Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.